Evidence map›Paper›PMID 21999571›Full record

ArticleBMC genomics2011

Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis.

Kasper Thorsen, Troels Schepeler, Bodil Øster, Mads H Rasmussen, Søren Vang, Kai Wang, Kristian Q Hansen, Philippe Lamy, Jakob Skou Pedersen, Asger Eller and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Role of LMO7 in cancer (Review).Oncology reports · 2024
    Review
  9. Oxysterols as Biomarkers of Aging and Disease.Advances in experimental medicine and biology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Functional Meaning of 5'UTR in Protein-Coding Genes.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Kasper ThorsenDepartment of Molecular Medicine, Aarhus University Hospital, Skejby, 8200 Aarhus N, Denmark.
Troels Schepeler
Bodil Øster
Mads H Rasmussen
Søren Vang
Kai Wang
Kristian Q Hansen
Philippe Lamy
Jakob Skou Pedersen
Asger Eller
Francisco Mansilla
Kirsti Laurila
Carsten Wiuf
Søren Laurberg
Lars Dyrskjøt
Torben F Ørntoft
Claus L Andersen
Aarhus University Hospital · DKAarhus University · DKHarvard University · USTampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately half of all human genes use alternative transcription start sites (TSSs) to control mRNA levels and broaden the transcriptional output in healthy tissues. Aberrant expression patterns promoting carcinogenesis, however, may arise from alternative promoter usage.

resultsBy profiling 108 colorectal samples using exon arrays, we identified nine genes (TCF12, OSBPL1A, TRAK1, ANK3, CHEK1, UGP2, LMO7, ACSL5, and SCIN) showing tumor-specific alternative TSS usage in both adenoma and cancer samples relative to normal mucosa. Analysis of independent exon array data sets corroborated these findings. Additionally, we confirmed the observed patterns for selected mRNAs using quantitative real-time reverse-transcription PCR. Interestingly, for some of the genes, the tumor-specific TSS usage was not restricted to colorectal cancer. A comprehensive survey of the nine genes in lung, bladder, liver, prostate, gastric, and brain cancer revealed significantly altered mRNA isoform ratios for CHEK1, OSBPL1A, and TCF12 in a subset of these cancer types.To identify the mechanism responsible for the shift in alternative TSS usage, we antagonized the Wnt-signaling pathway in DLD1 and Ls174T colorectal cancer cell lines, which remarkably led to a shift in the preferred TSS for both OSBPL1A and TRAK1. This indicated a regulatory role of the Wnt pathway in selecting TSS, possibly also involving TP53 and SOX9, as their transcription binding sites were enriched in the promoters of the tumor preferred isoforms together with their mRNA levels being increased in tumor samples. Finally, to evaluate the prognostic impact of the altered TSS usage, immunohistochemistry was used to show deregulation of the total protein levels of both TCF12 and OSBPL1A, corresponding to the mRNA levels observed. Furthermore, the level of nuclear TCF12 had a significant correlation to progression free survival in a cohort of 248 stage II colorectal cancer samples.

conclusionsAlternative TSS usage in colorectal adenoma and cancer samples has been shown for nine genes, and OSBPL1A and TRAK1 were found to be regulated in vitro by Wnt signaling. TCF12 protein expression was upregulated in cancer samples and correlated with progression free survival.

Indexed as

ExonsTranscription Initiation SiteAdaptor Proteins, Vesicular TransportAlternative SplicingBasic Helix-Loop-Helix ProteinsCarrier ProteinsCheckpoint Kinase 1Cohort StudiesColorectal NeoplasmsHumansOligonucleotide Array Sequence AnalysisOxysterol Binding ProteinsPromoter Regions, GeneticProtein IsoformsProtein KinasesReceptors, SteroidAdaptor Proteins, Vesicular TransportBasic Helix-Loop-Helix ProteinsCarrier ProteinsCheckpoint Kinase 1CHEK1 protein, humanOxysterol Binding ProteinsProtein IsoformsProtein KinasesReceptors, SteroidRNA, MessengerTCF12 protein, humanTRAK1 protein, human

Identifiers

PMID21999571
PMCPMC3208247
OpenAlexW2112067247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.